Clinical Trials Logo

Differentiated Thyroid Cancer clinical trials

View clinical trials related to Differentiated Thyroid Cancer.

Filter by:

NCT ID: NCT06458036 Not yet recruiting - Cancer Clinical Trials

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

RAISE
Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.

NCT ID: NCT06235216 Not yet recruiting - Clinical trials for Differentiated Thyroid Cancer

Sacituzumab govitEcan in THYroid Cancers

SETHY
Start date: February 2024
Phase: Phase 2
Study type: Interventional

SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC). The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.

NCT ID: NCT06154863 Not yet recruiting - Clinical trials for Differentiated Thyroid Cancer

Recurrence in Patients With Differentiated Thyroid Cancer

Start date: March 1, 2024
Phase:
Study type: Observational

The aim of this study is to assess the recurrence-free survival (RFS) rate and recurrence-related factors, especially the relationship between RFS and RAI dose, in patients who received RAI after thyroidectomy.

NCT ID: NCT05989425 Recruiting - Clinical trials for Differentiated Thyroid Cancer

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Start date: August 4, 2023
Phase: Phase 2
Study type: Interventional

Locally advanced thyroid cancer has a wide range of surgery, large trauma and high local recurrence rate. It is one of the main causes of death in patients with thyroid cancer. Therefore, more effective treatments are urgently needed. This study is designed to evaluate the efficacy and safety of the Surufatinib for Locally Advanced Thyroid Cancer.

NCT ID: NCT05852223 Recruiting - Clinical trials for Differentiated Thyroid Cancer

Pembrolizumab in High-risk Thyroid Cancer

NePenThe
Start date: April 2024
Phase: Phase 2
Study type: Interventional

This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.

NCT ID: NCT05789667 Recruiting - Clinical trials for Differentiated Thyroid Cancer

Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer

Gisel
Start date: May 27, 2020
Phase:
Study type: Observational

Lenvatinib is approved for the treatment of radioiodine refractory differentiated thyroid cancer. Despite gender can play a crucial role un in safety and efficacy of oncological product, little is know on gender difference in lenvatinb effacacy and safety in the context of radioiodine refractory differentiated thyroid cancer. The primary objective of the study is to assess safety and toxicity profile in male and female patients in terms of dose reduction. The secondary objectives are to assess sex and gender difference in: the number and the incidence of adverse events; response rate according to RECIST criteria 1.1; progression free survival, overall survival and duration of response.

NCT ID: NCT05783323 Recruiting - Cancer Clinical Trials

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Start date: February 14, 2024
Phase: Phase 2
Study type: Interventional

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.

NCT ID: NCT05745363 Recruiting - Clinical trials for Differentiated Thyroid Cancer

Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer

Start date: February 24, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib clinical trial to evaluate the efficacy and safety of AL2846 capsule in iodine-refractory differentiated thyroid cancer that has failed previous TKI treatment. The trial is planned to enroll 20 subjects. The trial is a single-arm, multi-center, open label clinical study. Objective response rate (ORR) is the primary endpoint.

NCT ID: NCT05660954 Recruiting - Clinical trials for Differentiated Thyroid Cancer

Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

CABOTHYROID
Start date: May 25, 2023
Phase: Phase 2
Study type: Interventional

CABOTHYROID is a prospective, exploratory, biomarker-focused, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of cabozantinib in patients with previously treated advanced radioactive-iodine refractory

NCT ID: NCT05604963 Recruiting - Clinical trials for Differentiated Thyroid Cancer

Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers

HoT
Start date: February 14, 2022
Phase: N/A
Study type: Interventional

This is a multi-centre, randomised, non-inferiority, phase III study in patients with low risk differentiated thyroid cancer. Patients will be identified via oncology multidisciplinary team meetings. There will be two sources of patients in the trial, with the same histological diagnoses and prognosis (i.e. recurrence risk): - Group 1: Patients who have already had a HT for thyroid problems and are then subsequently diagnosed with low risk DTC will be randomised 1:1 to undergo surveillance only OR a second operation to remove the rest of their thyroid gland (two-stage total thyroidectomy). - Group 2: Patients diagnosed with low risk DTC using cytology (Thy5) but no surgery performed will be randomised 1:1 to have either a hemi-thyroidectomy OR a single-stage total thyroidectomy. The overall aim of the trial is to determine whether hemithyroidectomy is an acceptable and cost-effective surgical procedure compared to total thyroidectomy in low risk thyroid cancer. Overall, 456 patients will be recruited to the trial. Patients will be initially be followed up post-surgery then 12 monthly for 6 years.